Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis (NOBICS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02801682
Recruitment Status : Recruiting
First Posted : June 16, 2016
Last Update Posted : October 23, 2019
Sponsor:
Collaborator:
Medical University Innsbruck
Information provided by (Responsible Party):
Robert Krause, MD, Medical University of Graz

Brief Summary:

Invasive Candida infections are serious complications in immunocompromised patients including those undergoing treatment for cancer but occur also in patients treated in ICUs. Survival rate of invasive candidiasis is associated with early initiation of antifungal therapy (15% mortality rate for candidemic patients with antifungal therapy on day 0 related to the culture date of the first blood sample positive for yeasts compared to 41% for patients who received antifungal therapy on day 3). Up to date, no laboratory method or clinical decision rule is available for correct anticipation of invasive candidiasis which would avoid delays in appropriate antifungal therapy initiation. In clinical practice culture based methods (e.g. blood cultures) miss up to 50% of invasive candidiasis cases. Preemptive antifungal therapy is therefore often initiated in critically ill patients after Candida has been isolated from various non-sterile patient samples even without any sufficient evidence for invasive candidiasis. The disadvantages of this approach include over- and undertreatment of patients (up to 50% of candidemia cases are missed, and on the other hand 89% patients are treated unnecessarily), increased selective pressure for the development of antifungal resistance, potential risk of adverse drug reactions, and increased costs (expenses for antifungal therapy account for half of the antimicrobial medication budget in tertiary care hospitals). In addition, no survival benefit could be demonstrated by this strategy in ICU patients.

The aim of this study is to identify biological markers to anticipate or support the diagnosis of invasive candidiasis in ICU patients, to overcome current deficiencies in detection of invasive candidiasis and consequently to differentiate between Candida spp. colonization and invasive Candida infection. The investigators intend to examine time dependent courses of potential host and pathogen derived biomarkers as well as innate or acquired predispositions for invasive candidiasis; e.g. automated (1→3) ß- D- Glucan tests, DNA in serum blood samples, pathogen recognition receptors and serum markers like interleukin (IL)-1, IL-2, IL-6, IL-10, IL-12, IL-17A, IL-17F, IL-22, IL-23, Tryptophan, Kynurenine, composition of indigenous microbiota of gastrointestinal and lower respiratory tract and skin, and risk factors for invasive candidiasis like underlying diseases and treatments. The study should contribute to improved assessment of ICU patients at risk for invasive candidiasis and to improved diagnosis of invasive candidiasis in ICU patients. In clinical practice the reliable differentiation between infection and colonization will allow more targeted antifungal therapy leading to enhanced antifungal treatment initiation on the one hand (in cases of true invasive candidiasis) and to reduction of unnecessary antifungal treatments and treatment costs on the other hand.


Condition or disease
Invasive Candidiasis

Layout table for study information
Study Type : Observational
Estimated Enrollment : 240 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis
Actual Study Start Date : June 2016
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine


Group/Cohort
Healthy Controls
Invasive Candidiasis
Bacterial Sepsis (Bacteremia)
ICU patients without infectious disease



Primary Outcome Measures :
  1. Biomarkers indicating or excluding invasive Candidiasis [ Time Frame: through study completion, an average of 2 years ]
    Automated (1→3) ß- D- Glucan tests (pg/ml) DNA in serum blood samples (quantity and sequences) pathogen recognition receptors (% of cells as assessed by FACS analysis) serum markers like IL-1, IL-2, IL-6, IL-10, IL-12, IL-17A, IL-17F, IL-22, IL-23, Tryptophan, Kynurenine (quantity) composition of indigenous microbiota of gastrointestinal and lower respiratory tract and skin (comparison of detection rates and abundances of different classes or genera)


Secondary Outcome Measures :
  1. Risk factors for Invasive Candidiasis [ Time Frame: through study completion, an average of 2 years ]
    Risk factors as described in previous literature, e.g. Eggimann, Lancet Infect Dis 2003; 3: 685-702



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
  1. Healthy subjects
  2. Patients with invasive candidiasis/Candida sepsis
  3. Patients with sepsis and bacteremia
  4. ICU Patients without infectious disease
Criteria

ad 1:

Inclusion Criteria:

-subjects without any evidence of current or chronic infectious diseases

Exclusion Criteria:

  • Clinical or radiological or laboratory evidence of current infectious disease (temperature >38°C, elevated CRP >5mg/dl, leukocytosis >11400, elevated neutrophiles)
  • antifungal therapy within 8 weeks prior to inclusion
  • immunosuppressive therapy (e.g. glucocorticoids, methotrexate, azathioprin, etc)
  • active haematooncological diseases
  • HIV positivity

ad 2:

Inclusion criteria:

-Patients with invasive Candidias/Candida sepsis as defined in recent EORTC/MSG definitions.

Exclusion criteria:

  • glucocorticoid treatment with prednisone equivalent of ≥20mg/d
  • inherited neutrophil deficiency
  • absolute neutrophil count of ≤500cells/mm3
  • antifungal therapy within 8 weeks prior to inclusion
  • immunosuppressive therapy (glucocorticoids with prednisone equivalent of ≥20mg/d, methotrexate, azathioprin etc)
  • active hematooncological disease
  • HIV positivity

ad 3:

Inclusion criteria:

-ICU patients with sepsis and proven bacteremia (Staph. aureus or E. coli)

Exclusion criteria:

  • Antifungal therapy within 8 weeks prior to inclusion
  • immunosuppressive therapy (glucocorticoids with prednisone equivalent of ≥20mg/d, methotrexate, azathioprin etc)
  • active hematooncological disease HIV positivity

ad 4:

Inclusion criteria:

-ICU patients without invasive candidiasis as defined above, without bacteremia and without clinical and laboratory markers of infection(e.g. intubated and mechanically ventilated patients with stroke or CPR)

Exclusion criteria:

  • Clinical or radiological or laboratory evidence of current infectious disease (temperature >38°C, elevated CRP >5mg/dl, leukocytosis >11400, elevated neutrophiles)
  • antifungal therapy within 8 weeks prior to inclusion
  • immunosuppressive therapy (e.g. glucocorticoids, methotrexate, azathioprin, etc)
  • active haematooncological diseases
  • HIV positivity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02801682


Contacts
Layout table for location contacts
Contact: Robert Krause, MD +43 316 385 ext 81796 robert.krause@medunigraz.at

Locations
Layout table for location information
Austria
Medical University of Graz Recruiting
Graz, Stmk, Austria, 8036
Contact: Robert Krause, MD    0043 316 385 81796    robert.krause@medunigraz.at   
Principal Investigator: Robert Krause, MD         
Sponsors and Collaborators
Medical University of Graz
Medical University Innsbruck
Investigators
Layout table for investigator information
Principal Investigator: Robert Krause, MD Section of Infectious Diseases and Tropical Medicine, Dpt of Internal Medicine, Medical University of Graz
Layout table for additonal information
Responsible Party: Robert Krause, MD, Univ.Prof.Dr., Medical University of Graz
ClinicalTrials.gov Identifier: NCT02801682    
Other Study ID Numbers: KLI 561-B31
First Posted: June 16, 2016    Key Record Dates
Last Update Posted: October 23, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Candidiasis
Candidiasis, Invasive
Mycoses
Invasive Fungal Infections